Yes! Easy peasy!Would it be ok to copy and paste the above provided bullet points?
Did you submitted your answers, Jay?
Yes! Easy peasy!Would it be ok to copy and paste the above provided bullet points?
The last thing I want to do is overwhelm people with more information but I added this to question 2 in my personal response, in the interest of transparency.Here's a more dense breakdown of the curative science referenced in question number one.
Bi-modal Stimulation
1) Dr. Susan Shore of the University of Michigan has been working on a bi-modal stimulation device for the specific treatment of tinnitus for the better part of two decades. Results from her phase one trial revealed "tinnitus reduction reached an average of 12.2 dB in the fourth week of active treatment...[and] of the 20 participants tested, 2 reported complete elimination of their tinnitus toward the end of the active treatment period". Additionally, Shore's bi-modal stimulation was compared to a placebo treatment of which no participants experienced such decrements in tinnitus volume. Shore's device is on pace to finish its final phase of testing (phase 2) in the summer of 2020.
References: 2) "Lenire" is a treatment that is currently available in Ireland. While Shore's device targets the neck or jaw, Lenire targets the tongue. It should be noted that the waiting list for patient approval is 2-4 months long, while the reception of the device can take another 2-4 months after confirming participation in the study. Results from clinical trials have been encouraging, but data have now been locked until August 2020; conversely, user reports on Tinnitus Talk have yielded equivocal results.
- Marks, K.L., Martel, D.T., Wu, C., Basura, G.J., Roberts, L.E., Schvartz-Leyzac, K.C., Shore, S.E. (2018). Auditory-somatosensory bimodal stimulation desynchronizes brain circuitry to reduce tinnitus in guinea pigs and humans. Science Translational Medicine, 10(422). Retrieved from https://stm.sciencemag.org/content/10/422/eaal3175
Inner Ear Hair Cell & Cochlear Regeneration Therapies
1) Frequency Therapeutics entered the hearing regeneration space with the formulation of an intratympanic drug, "FX-322." A first-in-class drug, FX-322 is "designed to treat the underlying cause of sensorineural hearing loss (SNHL) by regenerating hair cells through activation of progenitor cells already present in the cochlea." Since tinnitus is thought to be a consequence of hearing loss, logic follows that treating hearing loss will improve or remove tinnitus symptoms. Frequency Therapeutics' phase 1/2 results determined that four of fifteen participants who had been administered a single dose of FX-322 experienced 10dB improvements in thresholds at 8kHz. Further, those same four participants had clinically significant improvements in clarity of sound, doubling their word scores in a quiet background and experiencing a 20% improvement in word scores in a noisy background at 90-days post-administration. What's even more exciting is that not only has the FDA has granted FX-322 fast-track status for the treatment of sensorineural hearing loss (SNHL)(15), but that Frequency Therapeutics has added a tinnitus experimental arm to their phase 2 experiment(16), which is set to be complete by late 3Q 2020.
References:2) Of the 73 Hearing Research Program applicants vying for a Congressionally Directed Medical Research Programs (CDMRP) grant—only one company, Hough Ear Institute, was awarded the $1.9 million grant. Their drug—a free radical scavenger pill "HPN-07" passed phase 1 for safety in 2015 and a paper published in 2018 reported some remarkable findings. In a study wherein Sprague Dawley rats were induced to have permanently shifted their auditory thresholds via an open field acoustic blast insult, rats that were treated with HPN-07 plus N-acetylcysteine four weeks after the initial trauma exhibited restoration of inner hair cell (IHC) ribbon synapses. Hough Ear Institute has recently licensed exclusive rights of their hearing regeneration drug—now termed "NHPN-1010", a combination of HPN-07 and N-acetylcysteine—to Oblato Inc. who will be financing the drug through phase 2 clinical trials.
- Frequency Therapeutics. (n.d.) Our Sensorineural Hearing Loss Program. Retrieved from https://www.frequencytx.com/pipeline-programs/hearing-program/
- Frequency Therapeutics. (2020). Corporate Overview. 25-29. Retrieved from https://investors.frequencytx.com/static-files/6d161090-16f5-49f4-9606-8caceb5a88a1
- Park, B. (2019). FDA Grants Fast Track Status to FX-322 for Sensorineural Hearing Loss. Retrieved from https://www.empr.com/home/news/drug...tus-to-fx-322-for-sensorineural-hearing-loss/
- U.S. National Library of Medicine. (2020). FX-322 in Adults With Stable Sensorineural Hearing Loss. Retrieved from https://clinicaltrials.gov/ct2/show/NCT04120116
References:3) Two drugs are being formulated for the treatment of cochlear synaptopathy—a condition that concerns the degradation of auditory nerve fibers termed "hidden hearing loss," which chiefly manifests itself as a lack of clarity upon hearing speech-in-noise.
- Hough Ear Institute. (n.d.). Otologic Pharmaceutics and Hough Ear Institute Awarded Grant to Advance Cochlear Hair-Cell Regeneration Treatment. Retrieved from https://houghear.org/hei-awarded-grant-from-u-s-dept-of-defense/
- U.S. National Library of Medicine. (2015). Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC. Retrieved from https://clinicaltrials.gov/ct2/show/NCT02259595
- FPO. (2018). Methods For Enhancing Synaptogenesis and Neuritogenesis. Retrieved from http://www.freepatentsonline.com/y2018/0117115.html
- Hough Ear Institute. (2020). Oblato Biotech Company Acquires Hearing Loss Drug Discovered by Hough Ear Institute Scientists. Retrieved from https://www.prnewswire.com/news-rel...hough-ear-institute-scientists-301003204.html
3.1) Otonomy, Inc. are currently phase 1/2 trials with their sustained-release BDNF (brain-derived neurotrophic factor) drug, "OTO-413" with results expected in the second half of 2020. Non-clinical studies by Otonomy "have demonstrated that local administration of BDNF repairs ribbon synapses damaged due to noise trauma or exposure to ototoxic chemicals and restores hearing function."
References:
- Otonomy. (2019). Otonomy Initiating Phase ½ Clinical Trial of OTO-413 in Hearing Loss. Retrieved from https://investors.otonomy.com/news-releases/news-release-details/otonomy-initiating-phase-12-clinical-trial-oto-413-hearing-loss
3.2) Pipeline Therapeutics has developed "PIPE-505"—a gamma secretase inhibitor that aims to regenerate "the cochlear synapse, [which] should augment signal-to-noise processing and manifest as improved speech-in-noise comprehension." Their phase 1b/2a study is due to commence in the near future.
References:
- Pipeline Therapeutics. (n.d.). Synaptogenesis. Retrieved from https://www.pipelinetherapeutics.com/science/synaptogenesis.html
KV7 Potassium Channel Modulators
1) Professor Thanos Tzounopoulos received a $2 million grant in 2018 to finance research on "RL-81"—a reformulation of an epilepsy drug, "retigabine/ezogabine" which had been anecdotally reported to have diminished tinnitus symptoms. While the drug was discontinued in 2017 after the emergence of a host of problematic side-effects, many users on the Tinnitus Talk forums experienced a dose-response effect regarding relief of their symptoms.
References:2) Knopp Biosciences is developing a drug for epilepsy, "KB-3061" that is aimed to modulate the same channels as RL-81. While epilepsy is the company's primary target, they've list tinnitus as a potentially applicable condition.
- Srikameswaran, A. (2018). Pitt Researchers Awarded $2 Million Grant to Develop Drug for Tinnitus. Retrieved from https://inside.upmc.com/pitt-researchers-grant-tinnitus/
- Tinnitus Talk Support Forum. (2014). Retigabine (Trobalt, Potiga)—User Experiences. Retrieved from https://www.tinnitustalk.com/threads/retigabine-trobalt-potiga-—-user-experiences.6047/
References:I'd really like curative research to be highlighted in terms of its immediacy of need in hopes to expedite FDA approval/release timelines.
- Knopp Biosciences. (2019). Knopp Biosciences to Present Data Characterizing Its Potassium Channel Activator Candidate for the Treatment of KCNQ2 Epileptic Encephalopathy at the American Epilepsy Society's 2019 Annual Meeting. Retrieved from https://knoppbio.com/news/knopp-bio...merican-epilepsy-societys-2019-annual-meeting
- Knopp Biosciences. (n.d.). Addressing an unmet need. Retrieved from https://knoppbio.com/kv7-platform
Done! Huge thanks to the volunteers for all the time they put into this excellently researched template! I'm more pumped up than ever to continue lending my own skills to Tinnitus Talk (which you should all consider too ). Let's make some change happen!
Thank you, Martin!Done
Gracias, Adi!! Thank you!Done!
Thank you so much for helping out!!!Done.
Hey, Bambam0. Thank you for taking the time and sending your answers.Done! Thanks @Hazel for organizing!
As they say: you can lead a horse to water, but you can't make it drink.It's like pulling teeth here...bahaha… View attachment 37172
I want to see more...
View attachment 37173
View attachment 37174
Not yet. I've been busy with Law School work but I will either tonight or tomorrow!Yes! Easy peasy!
Did you submitted your answers, Jay?
Can we have friends/family that don't suffer from tinnitus send letters in as well or is this only for tinnitus/hyperacusis sufferers?It's like pulling teeth here...bahaha… View attachment 37172
I want to see more...
View attachment 37173 View attachment 37174
Can we have friends/family that don't suffer from tinnitus send letters in as well or is this only for tinnitus/hyperacusis sufferers?
Yes, please do share the link with your family and friends.Can we have friends/family that don't suffer from tinnitus send letters in as well or is this only for tinnitus/hyperacusis sufferers?
Done!
For question 1 I added an intro covering my situation in a few sentences. And for the rest of 1-5 I copied bits and pieces from provided answers that I thought were strongest and fit well together.
Thanks for the clear instructions, made it very easy!
@Autumnly I was waiting for your: Done! haha...Done. A huge thank you to everyone that worked on this initiative, the prepared answers helped me immensely!
Very good idea. Done!Can we see about having this post pinned in the support section as was done for Tinnitus Week @Markku? I feel like many people could be missing it here, the support section has much higher traffic.
I would have painted a darker picture of this condition (like tinnitus can lead to suicide, not only to suicidal thoughts).
Thank you, FGG!!! It is so important and we only have 2 more weeks before deadline.Done! Had to fight against my occasional tendency to wait until the last minute but this is too important!
Thank you, Frederic! You would think more people would be running to submit their answers.Done. As a Frenchman, I thought I would wait until the last moment to do it, and let our American friends do it first, but then I changed my mind. Come on guys, 30,000 members on this forum of which 50% are American, we should normally flood the mailbox of the NIDCD.
Right!?You would think more people would be running to submit their answers.